Omapatrilat Provides Long‐Term Control of Hypertension: A Randomized Trial of Treatment Withdrawal

Omapatrilat simultaneously inhibits neutral endopeptidase and angiotensin‐converting enzyme, increasing levels of vasodilatory peptides while decreasing production of angiotensin II. This study evaluated the clinical effects of withdrawal of omapatrilat after a patient's hypertension had been c...

Full description

Saved in:
Bibliographic Details
Published in:The journal of clinical hypertension (Greenwich, Conn.) Conn.), 2002-05, Vol.4 (3), p.169-172
Main Authors: Guthrie, Robert, Reeves, Richard A.
Format: Article
Language:English
Subjects:
Adult
Aged
Angiotensin-Converting Enzyme Inhibitors - administration & dosage
Blood Pressure Determination
Dose-Response Relationship, Drug
Drug Administration Schedule
Female
Follow-Up Studies
Humans
Hypertension - diagnosis
Hypertension - drug therapy
Male
Middle Aged
Original Papers
Pyridines - administration & dosage
Reference Values
Severity of Illness Index
Thiazepines - administration & dosage
Time Factors
Treatment Outcome
Withholding Treatment
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Omapatrilat simultaneously inhibits neutral endopeptidase and angiotensin‐converting enzyme, increasing levels of vasodilatory peptides while decreasing production of angiotensin II. This study evaluated the clinical effects of withdrawal of omapatrilat after a patient's hypertension had been controlled (seated diastolic blood pressure
ISSN:1524-6175
1751-7176
DOI:10.1111/j.1524-6175.2002.01400.x